Brokerages Set Teva Pharmaceutical Industries Limited (NYSE:TEVA) Target Price at $20.88

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eight analysts that are currently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $20.88.

TEVA has been the topic of a number of recent research reports. StockNews.com downgraded Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a report on Wednesday, December 18th. Barclays upped their target price on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 18th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, October 21st.

Insider Activity at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 286,000 shares of the firm's stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the sale, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now owns 44,104 shares of the company's stock, valued at approximately $744,034.48. This represents a 30.54 % decrease in their position. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently made changes to their positions in the company. UMB Bank n.a. lifted its holdings in shares of Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company's stock worth $44,000 after acquiring an additional 2,067 shares during the last quarter. Smithfield Trust Co raised its position in Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock valued at $50,000 after purchasing an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at about $50,000. Claro Advisors LLC acquired a new position in shares of Teva Pharmaceutical Industries during the third quarter worth about $52,000. Finally, Venturi Wealth Management LLC acquired a new stake in Teva Pharmaceutical Industries in the third quarter valued at approximately $60,000. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA opened at $21.09 on Monday. The stock has a market capitalization of $23.89 billion, a price-to-earnings ratio of -24.81, a PEG ratio of 0.99 and a beta of 0.73. Teva Pharmaceutical Industries has a 1-year low of $10.83 and a 1-year high of $22.80. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. The business's fifty day moving average price is $18.89 and its 200-day moving average price is $18.05.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.